Salix Coronary Plaque vs iCAC Device
AI Verdict
Choose Salix Coronary Plaque if…
Choose Salix Coronary Plaque if your primary need is a comprehensive, near real-time assessment of coronary artery plaque and stenosis from CCTA scans. This tool is ideal for detailed evaluation of plaque morphology, including high-risk features, to aid in rapid diagnosis and treatment planning for coronary artery disease.
View Salix Coronary Plaque →Choose iCAC Device if…
Choose iCAC Device if you aim for opportunistic screening and early detection of cardiovascular disease risk from routine, non-contrast, non-gated chest CT scans. This tool is best suited for identifying and quantifying coronary artery calcium from existing imaging data, enabling proactive risk stratification without requiring additional dedicated cardiac imaging.
View iCAC Device →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Salix Coronary Plaque | iCAC Device |
|---|---|---|
| Pricing | Contact for pricing | Contact for pricing |
| Deployment | Cloud | Software as a Medical Device (SaMD), integrates with PACS or DICOM router. Cloud-based (via Carebricks platform). |
| FDA Status | Yes AI-estimated | 1 AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Salix Coronary PlaqueTool A (Salix Coronary Plaque) emphasizes a web-based, near real-time, point-of-care assessment that delivers results in under 10 minutes with minimal user training and an intuitive interface. Its integrated workflow for both anatomy and plaque analysis within a single system streamlines the diagnostic process. While Tool B also integrates into existing workflows, Tool A's explicit focus on speed, ease of use, and reduced training requirements gives it a slight edge in immediate usability.
Clinical Value
Salix Coronary PlaqueTool A (Salix Coronary Plaque) offers a more comprehensive clinical assessment by detecting and quantifying coronary plaque, including high-risk features like low-attenuation plaque and stenosis, from CCTA scans. This detailed analysis provides deeper diagnostic insights crucial for advanced risk stratification and personalized treatment. Tool B (iCAC Device) focuses on opportunistic coronary artery calcium (CAC) scoring from routine non-contrast CTs, which is valuable for early detection but less granular than Tool A's plaque characterization.
Pricing & Value
Salix Coronary PlaqueTool A (Salix Coronary Plaque) provides a clear financial value proposition by explicitly stating a US CPT reimbursement rate of US$950 per assessment, effective January 1, 2026. This transparency regarding reimbursement offers a tangible benefit for healthcare providers. While Tool B (iCAC Device) has also secured a CMS reimbursement pathway, the specific reimbursement amount is not publicly detailed, making Tool A's pricing and value more transparent.
Enterprise Readiness
iCAC DeviceBoth tools are FDA-cleared and cloud-based, demonstrating foundational enterprise readiness. However, Tool B (iCAC Device) leverages its Carebricks platform to not only integrate with PACS/DICOM and EHRs but also to enable health systems to build and deploy 'AI agents' for automating complex, end-to-end workflows. This broader platform approach for operationalizing AI across the enterprise suggests a more advanced and flexible readiness for diverse healthcare system needs.
Innovation
iCAC DeviceWhile Tool A (Salix Coronary Plaque) is innovative in its detailed, near real-time CCTA analysis for high-risk plaque features, Tool B (iCAC Device) demonstrates broader innovation through its 'agentic AI' Carebricks platform. This platform allows for opportunistic CAC detection from routine, non-dedicated CT scans, significantly expanding early detection. Furthermore, Carebricks enables health systems to design and deploy AI agents that reason across full patient histories and automate actions, representing a more expansive and flexible approach to AI in healthcare.
Support & Docs
Salix Coronary PlaqueTool A (Salix Coronary Plaque) explicitly mentions offering 'onboarding and training, clinician engagement, and comprehensive technical support' to its customers, along with an accessible 'Artrya Salix User Guide'. While Tool B (iCAC Device) implies support through its platform's capabilities and contact information, Tool A's direct mention of a comprehensive support and training package provides greater transparency and assurance regarding post-implementation assistance.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Salix Coronary Plaque | iCAC Device |
|---|---|---|
| Product Name | Salix Coronary Plaque | iCAC Device |
| Company | Artrya Limited | Bunkerhill Health |
| Description | FDA-cleared, AI-driven, web-based software that provides near real-time, point-of-care assessment of coronary artery plaque and stenosis from CCTA scans, aiding in the rapid and accurate diagnosis of coronary artery disease. | FDA-cleared AI algorithm that detects and quantifies coronary artery calcium from routine, non-contrast, non-gated chest CT scans, aiding in early cardiovascular disease detection. |
| Key Features (Plaque/Calcium Analysis) | Detection and quantification of coronary plaque (atherosclerosis); Identification of high-risk plaque features (e.g., low-attenuation plaque, spotty calcification, positive remodeling, napkin-ring sign); Stenosis assessment; Quantification of calcifications (calcium scoring) | Estimates presence and quantity of coronary artery calcium (CAC); Delivers exact and four-category quantitative estimates of CAC burden in Agatston units |
| Input Scan Type | CCTA scans | Routine, non-contrast, non-gated chest CT scans |
Videos
Demos, reviews, and walkthroughs featuring Salix Coronary Plaque and iCAC Device.